Blog

CardioCel: 8 years on and still free from calcification

23, August, 2016

Posted In: Featured, Blog, Uncategorized

CardioCel® is proving to be one of the biggest game changers in the congenital heart defect repairs and reconstructions space, offering significant long-term benefits to patients. While other tissue patches can calcify up to 18 months post implantation in paediatric patients, the latest follow up data released by Admedus shows no evidence of calcification using […]

> Read more

Using the ADAPT engineering process to create durable tissue scaffolds

8, July, 2016

Posted In: Featured, Blog, Uncategorized

Admedus is an Australian-based healthcare company leading the world in regenerative medicine and tissue engineering research. Using its proprietary ADAPT® tissue engineering technology, Admedus can transform xenograft (animal) tissue into durable bio-scaffolds that can be used for soft tissue repair within patients. The medical technology was first brought to Australia over 20 years ago by […]

> Read more

Admedus a major distributor of infusion solutions

10, June, 2016

Posted In: Blog, Uncategorized

Many people would have heard about the great work Admedus is doing in the field of tissue engineering and immunotherapies, but fewer people would know that Admedus is also a major distributor of infusion solutions (intravenous products and infusion pumps) to hospitals in Australia and New Zealand. The highly successful infusion portfolio has been part […]

> Read more

A day with Europe’s leading cardiovascular surgeons

5, May, 2016

Posted In: Blog, Uncategorized

In April, I had the privilege of spending the day with over forty of Europe’s leading cardiovascular surgeons. The purpose – an Admedus workshop to discuss the use of CardioCel to reconstruct heart valves and its potential in the future treatment of heart valve disease. Held in Amsterdam, the experts meeting shed light on the critical issues and […]

> Read more

Are all cardiovascular tissue patches the same?

5, April, 2016

Posted In: Blog, Uncategorized

While some people may claim that all cardiovascular tissue patches (pericardial patches/bioscaffolds) are fundamentally the same, we know this is not the case. Surgeons and patients alike are searching for a bioscaffold that is safe, strong and durable. More specifically, they want a material that doesn’t calcify (harden) at the site of surgery and can […]

> Read more

Partnering in the healthcare industry

7, March, 2016

Posted In: Blog, Uncategorized

Recently we had the pleasure of presenting at BioMelbourne Network’s Health Technology Partnering Forum ‘Collaborate to Innovate: Approaches to Partnering’ in Melbourne. During the event a range of industry experts from Johnson & Johnson, Pfizer, Acrux, Hatchtech, University of Melbourne, GBS Venture Partners and Admedus all shared their views on the best approaches to partnering and […]

> Read more

Admedus next generation vaccine technology targets HPV

12, February, 2016

Posted In: Blog, Uncategorized

2016 is looking to be an important year for Admedus as our immunotherapy programs continue to progress well. Working with Professor Ian Frazer and his team, we are developing therapeutic vaccines to target human papillomavirus (HPV) and herpes simplex virus 2 (HSV-2). These vaccines address significant diseases with a huge unmet medical need and if successful, […]

> Read more

Reconstructing valves vs replacing them?

7, January, 2016

Posted In: Blog, Uncategorized

In our last blog, we discussed the current tendency by surgeons to turn to valve replacements for aortic valve repair, rather than reconstructing the valve, even though replacement options are associated with sub-optimal outcomes. The use of replacements is partly due to the fact that surgeons did not have a tissue scaffold to reconstruct the […]

> Read more

Reconstructing the aortic valve using CardioCel®

1, December, 2015

Posted In: Blog, Uncategorized

Aortic valve disease is the most common cardiac anomaly and is often associated with leaflet defects. Traditionally, aortic valves have been replaced with a bio-prosthetic or mechanical heart valve, even though these replacement methods were associated with suboptimal outcomes such as calcification resulting in re-operation. While far from the optimal choice, the need to use […]

> Read more

World Health Organisation: You probably have herpes

6, November, 2015

Posted In: Blog, Uncategorized

“We really need to accelerate the development of vaccines against herpes simplex virus.” Sami Gottlieb, WHO medical officer. Figures released by the World Health Organisation (WHO) last week stated that 417 million people in the age group 15-49 age group are living with HSV-2. The recent estimates highlight not only the significance of this virus, […]

> Read more